Artikel ; Online: Inhibition of osteoclastogenesis for periprosthetic osteolysis therapy through the suppression of p38 signaling by fraxetin.
International journal of molecular medicine
2018 Band 42, Heft 3, Seite(n) 1257–1264
Abstract: Periprosthetic osteolysis belongs to osteolytic diseases, which often occur due to an imbalance between osteoclast and osteoblast number or activity. Fraxetin, a natural plant extract, inhibits osteoblast apoptosis and has therapeutic potential for ... ...
Abstract | Periprosthetic osteolysis belongs to osteolytic diseases, which often occur due to an imbalance between osteoclast and osteoblast number or activity. Fraxetin, a natural plant extract, inhibits osteoblast apoptosis and has therapeutic potential for treating osteolytic diseases. However, data pertaining to the effects of fraxetin on osteoclasts are limited. In the present study, it was demonstrated that the inhibition of osteoclastogenesis by fraxetin had an important role on the therapy of titanium particle‑induced osteolysis in vivo. In addition, fraxetin was demonstrated to suppress receptor activator of nuclear factor‑κB ligand (RANKL)‑mediated osteoclast differentiation and bone resorption in vitro in a dose‑dependent manner. Fraxetin inhibited osteoclast differentiation and function through the suppression of p38 signaling and subsequently, the suppression of osteoclast‑specific gene expression, including tartrate‑resistant acid phosphatase, nuclear factor of activated T‑cells, cytoplasmic 1, and cathepsin K. In conclusion, fraxetin administration may have potential as a treatment method for periprosthetic osteolysis and other osteolytic diseases. |
---|---|
Mesh-Begriff(e) | Animals ; Coumarins/pharmacology ; Male ; Mice ; Mice, Inbred C57BL ; Osteoclasts/cytology ; Osteoclasts/drug effects ; Osteogenesis/drug effects ; Osteolysis/metabolism ; RANK Ligand/metabolism ; RAW 264.7 Cells ; Reverse Transcriptase Polymerase Chain Reaction ; p38 Mitogen-Activated Protein Kinases/metabolism |
Chemische Substanzen | Coumarins ; RANK Ligand ; fraxetin (CD3GD44O3K) ; p38 Mitogen-Activated Protein Kinases (EC 2.7.11.24) |
Sprache | Englisch |
Erscheinungsdatum | 2018-05-21 |
Erscheinungsland | Greece |
Dokumenttyp | Journal Article |
ZDB-ID | 1444428-8 |
ISSN | 1791-244X ; 1107-3756 |
ISSN (online) | 1791-244X |
ISSN | 1107-3756 |
DOI | 10.3892/ijmm.2018.3698 |
Datenquelle | MEDical Literature Analysis and Retrieval System OnLINE |
Zusatzmaterialien
Kategorien
Verfügbar in ZB MED Köln/Königswinter
Zs.A 4942: Hefte anzeigen | Standort: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG) |
Über subito bestellen
Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.